Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studiesinforming on its efficacy, use, and adverse features-and there are also over 7.5 million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008-focusing on efficacy, side effects, and utility.
INTRODUCTION

GLOBAL EXPERIENCE AND POSITION IN GUIDELINES
As of the end of 2014, it is estimated that over 7.5 million person-years of tenofovir have been Though cohorts can provide some supportive data on efficacy, their main use has been in delineating toxicities and adverse events and they will therefore be discussed predominately in later sections. Much of the informative data has been from studies in patients naïve to ART, though there have also been some important switch studies published.
Naïve Studies
The main naïve studies of note have either utilized TDF as part of the nucleoside/ nucleotide backbone for studies of third agents; investigated the single-tablet regimens (STRs) that have been developed which contain TDF; or have specifically examined TDF compared to other nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)-principally abacavir.
Studies Comparing NRTIs
In the latter area-TDF compared to other NRTIs-the pivotal study since the last review has been the ACTG 5202 trial (ClinicalTrials.gov number, NCT00118898) [3, 4] . This placebo- Table 1 and many of the newer agents still under development continue to be studied primarily in combination with tenofovir/ emtricitabine.
The majority of these studies utilized TDF in both arms and therefore give little insight into the efficacy and utility of tenofovir as compared to other NRTIs, but they do give a wealth of encouraging data on the suitability of pairing these third agents with this nucleotide reverse transcriptase inhibitor-which can then be used to inform clinical practice on which combinations of anti-retroviral agents to use in individual patients. As with the studies listed in the preceding section, these trials reveal little on the efficacy or utility of TDF itself compared to other NRTIs, but do provide good data to support its use as part of these STRs.
Switch Studies
There have been switch studies designed to demonstrate data on the comparative efficacy and utility of tenofovir. BICOMBO It must however be acknowledged that all switch studies have inherent biases that may influence results.
Other Knowledge Gained from Studies
We have also acquired data on the forgiveness of TDF/emtricitabine/efavirenz (Atripla) in terms of viral breakthrough and resistance 
TOLERABILITY AND TOXICITY
In 2008, 7 years after its licensing as an antiretroviral, Pozniak [1] reported on the safety of TDF and concluded that a considerable amount of clinical data and experience supported the favorable tolerability of TDF. With a further 7 years of clinical experience, it is timely to rereview its safety profile.
General
Tenofovir disoproxil fumarate, and the FDCs that contain this NRTI, are generally well tolerated by HIV-infected patients with the most reported adverse events being some dizziness and gastro-intestinal discomfort (i.e., low-grade diarrhea and nausea), rarely significant enough to cause discontinuation Increased phosphaturia, normoglycemic glucosuria, and aminoaciduria are markers of proximal tubular dysfunction, and periodic evaluation for these may aid in the diagnosis of incipient tubular injury. Maggi et al. [54] evaluated TDF-induced tubular dysfunction in patients randomly assigned to either a TDF-or abacavir-containing regimen through analysis of urinary excretion of phosphate and uric acid.
Although there was no significant variation in eGFR, there was a significant increase in urinary excretion of phosphate in patients on TDF compared to those on abacavir after 6 and 12 months. To date, no long-term follow-up studies have yet reported on the development of early tubular dysfunction markers over time while on TDF.
Pregnancy and Breast Milk
There are only a very limited number of studies evaluating the pharmacokinetic profile of TDF during pregnancy. TDF has been shown to cross the placenta resulting in significant fetal concentrations (as measured by paired maternal plasma and umbilical cord samples) [55] . However, there appears to be no increased rate of fetal abnormalities in studies nor in the Anti-Retroviral Pregnancy Registry in those receiving this NRTI [56] . Of 1800 reported pregnancies where the mother had taken TDF, no increased rates of congenital abnormalities above controls have been seen. The number of exposed women was expected to have been sufficient to detect at least a 1.5-fold increase in risk of overall birth defects and a twofold increase in risk of birth defects in the more common classes-cardiovascular and genitourinary systems. A similar observation was noted in the DART trial (controlledtrials.com number, ISRCTN13968779) with no increase in congenital, renal, or growth abnormalities with in utero tenofovir exposure [57] .
To date, the main study evaluating TDF concentrations in breast milk was performed in Côte d'Ivoire in a small group of 5 women with 16 breast milk samples [58] . TDF is excreted in breast milk although in very small concentrations (0.03% of the proposed oral infant dose).
Bone
Compared to the general population, HIVinfected patients are at increased risk of developing osteoporosis and fractures [59, 60] .
A meta-analysis of cross-sectional studies using dual-energy X-ray absorptiometry to measure bone mineral density (BMD) demonstrated reduced BMD and increased rates of osteoporosis in HIV-infected versus non-HIVinfected patients (pooled odds ratios of 6.4 and 3.7, respectively) [59] .
The etiology of osteoporosis in HIV-infected patients is multifactorial with traditional risk factors, such as hypogonadism, low vitamin D, smoking, age, and low body weight being at least partially responsible [61] . Low nadir CD4 cell counts have been associated with larger declines in BMD [62] . It is probable that HIVrelated immune activation may also be a causative factor, with cytokines such as OPG and RANKL (associated with osteoclast activation and bone resorption) being present at higher concentrations in untreated HIVinfected patients compared to those with treated HIV or non-HIV-infected controls [63] .
However, anti-retroviral agents have also been implicated in causing osteoporosis [64] [65] [66] -with several studies specifically focusing on the potential association with TDF [27, 67, 68] . In the randomized ASSERT study, patients on TDF had a significantly greater decline in hip BMD compared to those in the abacavir arm (-3.5% versus -2.2% at week 96) [5] . Furthermore, bone turnover markers like P1NP, osteocalcin, and alkaline phosphatase were increased in those receiving TDF compared to those on abacavir at both week 48 and week 96 [5, 69] . Similarly, individuals using TDF for PrEP demonstrated small but statistically significant declines in BMD at the total hip (0.8-1.1% at months 24-30) and femoral neck (1.51% at month 30) compared to placebo [70, 71] . Long-term exposure to TDF has also been shown to be associated with an increased risk of osteoporotic fracture [72] .
Overall, however, it appears that the main impact of anti-retrovirals (including TDF) on BMD is within the first 48 weeks of commencement, with apparent stabilization subsequently [73] . It is unclear whether the impact is diminished in those already stabilized on anti-retrovirals before switching to TDF (as seen in the BICOMBO [14, 74] and STEAL studies [75] 
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CONCLUSIONS
With more than 7.5 million person-years of TDF experience and many pivotal clinical studies, tenofovir has proven to be a very effective and generally safe drug. There are potential issues related to renal dysfunction and BMD, however, this medication has been a pivotal component of successful anti-retroviral regimens for many patients globally.
In the next few years, TDF will become available as a generic drug in most parts of the world, tenofovir is likely to find a niche in PrEP, and the disoproxil formulation may be partly superseded by TAF in Western nations. TAF is also being made available to generic manufacturers to allow the production of affordable products in developing countries.
Tenofovir is therefore likely to remain of great utility in HIV for many years to come.
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